Fig. 3From: Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare settingBleeding eventsrAHF-PFM: antihemophilic factor (recombinant) plasma/albumin-free method; BAY: BAY 81–8973Back to article page